Two brain-penetrant incretin programmes

KP405

A dual GLP-1/GIP receptor agonist with a short cell-penetrating sequence to help it cross the blood-brain barrier. KP405 has completed Phase I in healthy volunteers, healthy older adults and people with Parkinson's.

A placebo-controlled Phase IIa in people with Parkinson's is in preparation with MAC Clinical Research in the UK. It includes blood-based brain biomarkers from NeuroDex and digital eye-movement measures from NeuraLight.

KP404

A dual GLP-1/GIP receptor agonist from the same series, carrying a poly-lysine extension in place of KP405's cell-penetrating sequence. KP404 is in preclinical development for Alzheimer's disease.